Feedback / Questions
bryostatin 1 (NSC 339555) - Synaptogenix
https://www.prnewswire.com/news-releases/synaptogenix-advances-dosing-of-first-patient-in-dose-optimization-clinical-trial-in-preparation-for-nih-sponsored-phase-2-alzheimers-disease-trial-data-301589937.html
Jul 20, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next